Digest Réseau Comment ça marche
Réseau
/
Sociétés
Sa
Non vérifié

Santhera Pharmaceuticals Holding AG

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

43 communiqués de presse

Voir tous les communiqués de presse
04/05/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Publishes Agenda for its Annual General Meeting
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
29/04/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Médecine Santé Bien-être
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
27/04/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Médecine Santé Bien-être
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
27/04/2026
Biotechnologie
Annonces Économiques
Management/Organisation d'Entreprise
Médecine Santé Bien-être
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
26/04/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
22/04/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Médecine Santé Bien-être
Santhera Appoints Orlando Oliveira as Chief Executive Officer
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
11/03/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Full Year 2025 Trading Update
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
09/03/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Annonces Économiques
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
08/03/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy  
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0
26/02/2026
Biotechnologie
Publicité/Marketing/Médias/Communication
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
Source
Santhera Pharmaceuticals Holding AG
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0